

POSTER PRESENTATION

Open Access

# Antiviral treatment in severe acute hepatitis B

Anca Streinu-Cercel<sup>1,2\*</sup>, Oana Streinu-Cercel<sup>1,2</sup>, Alina Cristina Negut<sup>1,2</sup>, Marius Stefan<sup>3</sup>, Adrian Streinu-Cercel<sup>1,2</sup>

From Abstracts from International Symposium HIV and Emerging Infectious Diseases 2014  
Marseille, France. 21-23 May 2013

## Introduction

We aimed to evaluate the clinical, biological and virological impact of antiviral therapy in severe acute hepatitis B. [1]

## Materials and methods

We performed a study in the National Institute for Infectious Diseases “Prof. Dr. Matei Bals”, Bucharest, Romania, randomizing patients between two groups initially: therapy with lamivudine 100 mg/day vs. standard of care (no antiviral therapy) and subsequently between three groups: lamivudine, standard of care and entecavir 0.5 mg/day, when this new analogue became available in Romania.

## Results

HBs antigen to antibody seroconversion was recorded by 24 weeks in 10.1% of the patients in the lamivudine group ( $p=0.032$  compared to control), 42.9% of those in the entecavir group ( $p=0.053$  compared to control), and 22.7% in the control (standard of care) group.

## Conclusions

If antiviral therapy is to be considered in severe acute hepatitis B, entecavir could be regarded as an option, as it might increase the chance of HBs antigen to antibody seroconversion when administered in the first 24 weeks of infection. [2,3] However, further studies are required to ascertain this, and to eventually determine the magnitude of the effect.

## Authors' details

<sup>1</sup>Department of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. <sup>2</sup>National Institute for Infectious Diseases, Bucharest, Romania. <sup>3</sup>Polytechnic University of Bucharest, Romania.

Published: 23 May 2014

<sup>1</sup>Department of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania  
Full list of author information is available at the end of the article

## References

1. Streinu-Cercel A: **Hepatitis B in the spotlight.** *GERMS* 2011, **1**(1):5.
2. De Socio GV, Sgrelli A, Tosti A, Baldelli F: **Severe acute hepatitis B treated with entecavir.** *Mediterr J Hematol Infect Dis* 2011, **3**(1):e2011010.
3. Streinu-Cercel O, Streinu-Cercel A, Preotescu LL, Streinu-Cercel A: **Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B.** *GERMS* 2012, **2**(1):18-22.

doi:10.1186/1471-2334-14-S2-P90

**Cite this article as:** Streinu-Cercel et al.: Antiviral treatment in severe acute hepatitis B. *BMC Infectious Diseases* 2014 **14**(Suppl 2):P90.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

